---
title: "Alkem Laboratories Ltd (ALKEM) — Share Price, Financials & Analysis"
symbol: "ALKEM"
company: "Alkem Laboratories Ltd"
canonical: "https://tapetide.com/stocks/ALKEM"
isin: "INE540L01014"
nse_symbol: "ALKEM"
bse_code: "539523"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 60655.32
generated_at: "2026-09-13T19:35:52.254Z"
---

# Alkem Laboratories Ltd (ALKEM)

Canonical page: https://tapetide.com/stocks/ALKEM

## Company

- **NSE Symbol:** ALKEM
- **BSE Code:** 539523
- **ISIN:** INE540L01014
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2015-12-23
- **CEO:** Mr. Basudeo Narian Singh
- **Employees:** 18785
- **Face Value:** ₹2
- **F&O Eligible:** Yes
- **Website:** alkemlabs.com

## About

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

## Latest Price

- **Price:** ₹5087.5
- **Change:** -50.5 (-0.98%)
- **Open:** ₹5122
- **Day High:** ₹5128
- **Day Low:** ₹5051
- **Previous Close:** ₹5138
- **Volume:** 238760
- **As Of:** 2026-09-11T10:20:13+00:00

## Key Fundamentals

Observed at 2026-09-11T04:34:32.846056Z.

- **Market Cap:** ₹60655.32 Cr
- **Classification:** Midcap
- **P/E (reported):** 27.7
- **P/E (TTM):** 28.19
- **EPS (TTM):** ₹180.45
- **EPS (reported):** ₹179.8
- **Book Value:** ₹1155.87
- **Price to Book:** 4.42
- **Dividend Yield:** 1.03%
- **ROE:** 16.4%
- **ROCE:** 18.84%
- **Debt to Equity:** 0.15
- **Revenue (yearly):** ₹15295.6 Cr
- **Net Income:** ₹2353.1 Cr
- **EBITDA:** ₹3588.6 Cr
- **52-Week High:** ₹5933.5
- **52-Week Low:** ₹5075
- **RSI (14):** 31.43

## Tapetide Score

- **Score:** 50 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Falling
- **Percentile:** 47.7 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 59.46 | 9% |
| growth | 33.17 | 9% |
| momentum | 11.75 | 12% |
| ownership | 45.09 | 24% |
| quality | 48.46 | 22% |
| valuation | 80.13 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has been maintaining a healthy dividend payout of 26.3%

### Weaknesses

- Promoter holding has decreased over last quarter: -1.50%
- The company has delivered a poor sales growth of 10.7% over past five years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 2.62% | 0.77% | 76.69% |
| ebitda margin growth | 57.73% | 5.06% | 19.09% | 14.33% |
| net income growth | 107.49% | 6.19% | 32% | 9% |
| revenue growth | 2.35% | 13.65% | 8% | 11% |
| roce | 71.71% | -2.33% | 2.17% | 18.22% |
| roe | 107.47% | -7.97% | 17.04% | -13.64% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 3440 | 3324 | 2936 | 3032 | 3415 | 3374 | 3144 | 3371 | 4001 | 3737 | 3603 | 3740 |
| Expenses | 2693 | 2616 | 2534 | 2423 | 2662 | 2615 | 2752 | 2632 | 3080 | 2909 | 3086 | 2974 |
| Operating Profit | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 |
| OPM % | 22 | 21 | 14 | 20 | 22 | 23 | 12 | 22 | 23 | 22 | 14 | 20 |
| Other Income | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 |
| Interest | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 |
| Depreciation | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 |
| Profit before tax | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 |
| Tax % | 5 | 8 | 17 | 11 | 10 | 12 | 18 | 13 | 13 | 16 | 40 | 32 |
| Net Profit | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| EPS in Rs | 51.9 | 49.76 | 24.55 | 45.6 | 57.6 | 52.34 | 25.58 | 55.56 | 63.99 | 53.19 | 19.78 | 43.49 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 6401 | 7357 | 8344 | 8865 | 10634 | 11599 | 12668 | 12965 | 14712 | 15081 |
| Expenses | 5392 | 6237 | 6868 | 6920 | 8580 | 9977 | 10419 | 10452 | 11706 | 12049 |
| Operating Profit | 1009 | 1120 | 1476 | 1945 | 2054 | 1622 | 2249 | 2512 | 3007 | 3032 |
| OPM % | 16 | 15 | 18 | 22 | 19 | 14 | 18 | 19 | 20 | 20 |
| Other Income | 115 | 82 | 102 | 230 | 146 | 101 | 186 | 494 | 407 | 412 |
| Interest | 55 | 55 | 65 | 59 | 52 | 107 | 112 | 122 | 161 | 178 |
| Depreciation | 143 | 193 | 253 | 275 | 304 | 310 | 299 | 357 | 382 | 395 |
| Profit before tax | 926 | 955 | 1260 | 1842 | 1844 | 1305 | 2023 | 2527 | 2871 | 2872 |
| Tax % | 31 | 19 | 9 | 12 | 9 | 23 | 10 | 12 | 18 | — |
| Net Profit | 638 | 774 | 1149 | 1618 | 1680 | 1007 | 1811 | 2215 | 2351 | 2204 |
| EPS in Rs | 52.77 | 63.61 | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 | 180.45 |
| Dividend Payout % | 25 | 25 | 27 | 23 | 25 | 61 | 27 | 25 | 28 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 4444 | 4840 | 5415 | 6137 | 7353 | 8614 | 9021 | 10288 | 11961 | 13796 |
| Borrowings | 659 | 998 | 944 | 1616 | 1707 | 2668 | 1397 | 1418 | 1381 | 2047 |
| Other Liabilities | 1440 | 1803 | 1824 | 2169 | 2435 | 2763 | 3315 | 3844 | 4325 | 4991 |
| Total Liabilities | 6568 | 7664 | 8208 | 9946 | 11519 | 14069 | 13757 | 15575 | 17691 | 20858 |
| Fixed Assets | 1797 | 2284 | 2530 | 2908 | 2793 | 2902 | 2683 | 2873 | 2852 | 3871 |
| CWIP | 299 | 381 | 493 | 363 | 393 | 339 | 323 | 159 | 548 | 282 |
| Investments | 553 | 444 | 324 | 261 | 333 | 371 | 622 | 484 | 1846 | 1869 |
| Other Assets | 3918 | 4555 | 4861 | 6413 | 8000 | 10457 | 10129 | 12060 | 12445 | 14836 |
| Total Assets | 6568 | 7664 | 8208 | 9946 | 11519 | 14069 | 13757 | 15575 | 17691 | 20858 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 471 | 266 | 780 | 585 | 1265 | 1111 | 1682 | 1948 | 1913 | 1963 |
| Cash from Investing Activity | -294 | -351 | -318 | -737 | -995 | -1433 | 120 | -1011 | -1288 | -1682 |
| Cash from Financing Activity | -138 | 85 | -379 | 79 | -272 | 380 | -1761 | -1145 | -811 | -503 |
| Net Cash Flow | 40 | 0 | 82 | -73 | -2 | 58 | 42 | -207 | -186 | -222 |
| Free Cash Flow | -163 | -411 | 253 | 237 | 1116 | 783 | 1453 | 1761 | 1278 | 1476 |
| CFO/OP | 73 | 47 | 92 | 59 | 86 | 73 | 121 | 105 | 96 | 86 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 46 | 62 | 62 | 72 | 66 | 65 | 67 | 65 | 69 | 74 |
| Inventory Days | 198 | 221 | 186 | 198 | 241 | 262 | 194 | 197 | 224 | 239 |
| Days Payable | 122 | 147 | 119 | 104 | 112 | 102 | 87 | 129 | 148 | 161 |
| Cash Conversion Cycle | 122 | 135 | 129 | 167 | 196 | 225 | 174 | 132 | 145 | 152 |
| Working Capital Days | 34 | 40 | 55 | 44 | 48 | 31 | 66 | 135 | 123 | 123 |
| ROCE % | 21 | 17 | 16 | 18 | 22 | 18 | 14 | 20 | 20 | 21 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 56.74% | 56.74% | 56.74% | 56.38% | 55.66% | 55.66% | 55.13% | 53.04% | 51.2% | 51.2% | 51.2% | 49.7% |
| FIIs | 6.03% | 8.49% | 9.11% | 8.69% | 9.02% | 10.15% | 9.41% | 9.11% | 9.48% | 9.97% | 10.16% | 10.42% |
| DIIs | 17.64% | 14.94% | 15.63% | 18.57% | 19.21% | 18.01% | 19.42% | 21.8% | 21.93% | 21.54% | 21.4% | 22.63% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 19.36% | 18.6% | 18.31% | 16.15% | 15.84% | 15.9% | 15.77% | 15.69% | 17.18% | 17.09% | 17.06% | 17.04% |
| Others | 0.23% | 1.23% | 0.21% | 0.21% | 0.26% | 0.28% | 0.28% | 0.36% | 0.22% | 0.21% | 0.19% | 0.21% |
| No. of Shareholders | 69442 | 65184 | 65830 | 69627 | 74744 | 84038 | 84326 | 79740 | 67196 | 64536 | 62835 | 62822 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 5 / 2 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 5201.05 | Sell |
| EMA (10) | 5195.59 | Sell |
| SMA (20) | 5286.93 | Sell |
| EMA (20) | 5277.91 | Sell |
| SMA (50) | 5486.82 | Sell |
| EMA (50) | 5393.5 | Sell |
| SMA (100) | 5453.53 | Sell |
| EMA (100) | 5440.53 | Sell |
| SMA (200) | 5510.88 | Sell |
| EMA (200) | 5423.88 | Sell |

### Oscillators — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 28.73 | Buy |
| MACD (12,26,9) | -100.91 | Sell |
| Stochastic (14,3,3) | 10.41 | Buy |
| ADX (14) | 34.25 | Buy |
| Williams %R (14) | -89.73 | Buy |
| ATR (14) | 101.88 | Neutral |
| ROC (12) | -4.07 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 50.99 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 11 | 55% |
| Hold | 6 | 30% |
| Sell | 3 | 15% |

Based on 20 analyst ratings, observed at 2026-09-11T04:34:32.926349+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-08 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68197ec5-666d-46b9-907e-923741043d3e.pdf) |
| 2026-08-27 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5bde1c9-28ad-4cf3-8ff4-b45d2515afab.pdf) |
| 2026-08-27 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e93802a-d529-42de-a11d-afc95adb2bbd.pdf) |
| 2026-08-26 | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=240F3C57_FE25_4C38_A750_8345FA7CCB50_172333.pdf) |
| 2026-08-17 | [Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5eb6e92a-c1e4-42ab-a8e2-453a7866afa1.pdf) |
| 2026-08-15 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1eddcc13-604e-40b7-b158-014bbce472b1.pdf) |
| 2026-08-14 | [Board Meeting Outcome for Outcome Of Board Meeting Dated 14/08/2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd922f32-f20c-4471-8bd1-d14044e85a28.pdf) |
| 2026-08-14 | [Announcement Under Reg 30 (LODR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f0998d1-9c91-488d-87f2-38bb1998c09c.pdf) |
| 2026-08-14 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43cbe2bf-b88f-48f2-8448-5ae99ab02385.pdf) |
| 2026-08-06 | [Update On US FDA Inspection At CompanyS Manufacturing Facility Located At Amaliya Daman](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6093b776-4786-425e-8450-b9853403301c.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e35df9c8-98f4-466e-811c-0637f12e3862.pdf) |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=994702db-fe4d-429d-bf12-a23c42c7275c.pdf) |
| 2026-06-01 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65750fe0-662a-48ca-a015-e770c0a7f0e7.pdf) |
| 2026-02-16 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a15cf9d7-1ac0-4b20-bb95-fc49544c1487.pdf) |
| 2025-11-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ecd03561-909d-4fcd-b57b-fb455bd2da51.pdf) |
| 2025-08-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0cd83f78-d535-4c6a-85a2-5f4a74bb6a9c.pdf) |
| 2025-06-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee0be198-db18-479e-88c2-1338f8249b2f.pdf) |
| 2025-02-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=667168ff-f380-4900-b24c-305bf284e725.pdf) |
| 2024-11-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42c6bd93-e92a-4faf-a759-d5d6eaad0470.pdf) |
| 2024-08-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4b327f3-1bb1-4659-a93f-d9e4f5e73886.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-14 | [Results- Unaudited Financial Results For Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=457296ba-3f1c-4a59-ae02-467cd8f1667b.pdf) |
| 2026-05-28 | [Results- Audited Financials Results For The Quarter And Year Ended 31St March 26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2f119cc-5a16-44cb-81dd-bf70baa93a01.pdf) |
| 2026-02-13 | [Results- Unaudited Financial Results For Quarter And Nine Months Ended 31St Dec 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=30c3b679-456c-49a2-93e3-9541610a5a6f.pdf) |
| 2025-11-13 | [Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5525273b-314a-433f-9fc2-d09b39fcf1aa.pdf) |
| 2025-08-12 | [Results- Unaudited Financial Results For Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea91a609-60ad-46b1-8ed3-a996c6833f70.pdf) |
| 2025-05-29 | [Results- Please Find Enclosed Herewith The Outcome Of Board Meeting Dated 29Th May 2025. Kindly Take The Same On Record.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eea44f2e-4fcb-417a-aa7b-eafa677831ed.pdf) |
| 2025-02-07 | [Results- Financials Results For Quarter Ended Dec 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86c00b50-0fba-4f99-91fe-f4d527120165.pdf) |
| 2025-02-07 | [Results- Financial Results For Quarter Ended Dec 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=062753e0-91e1-4f24-9aea-9f1bac587202.pdf) |
| 2024-11-13 | [Results- Financial Results For Quarter And Half Year Ended Sept 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=554b9f90-845c-46ad-8d2b-784e01161985.pdf) |
| 2024-08-09 | [Results- Financial Results For Quarter Ended 30Th June, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2d4b176e-bc96-4e8f-aa42-10611b0692eb.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=efcd8c7a-7f1f-4760-8279-0af90b7a2514.pdf) |
| 2026-05-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c37b0aa5-9080-4d74-84e1-9e69ac8102cd.pdf) |
| 2026-02-18 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4778b50-6dd4-4b8c-96a6-cdb9511b3988.pdf) |
| 2026-02-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=53c93086-b4dd-4832-a634-9bae3e40762e.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=535e4722-853b-4f09-832f-7a5b3c2be1b2.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6491c139-e5e1-45cd-b7d3-06397d76eafe.pdf) |
| 2025-08-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1f8c5cb-6cae-4760-a9b6-7a66c0c675f3.pdf) |
| 2025-05-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=71c50ff3-d72d-4199-bccb-033e5693691e.pdf) |
| 2025-03-19 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=111cd47b-bf95-48b5-87c1-5a8fbed12ef4.pdf) |
| 2025-02-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2fb5c609-f19d-4f1c-860b-8886d45c002d.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a8575d2e-dbc3-4c33-92f0-0e023610af91.pdf) |
| 2026-05-28 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=48973df3-d63b-4ac2-a78a-271663c216ac.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c6e4fe1-af9f-48de-a50f-22d044e1e132.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e47c811-9bc3-4aaa-9b45-73b7414e2cec.pdf) |
| 2025-08-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8792fe7-c9fe-43c3-9a26-3f8f3c8c5245.pdf) |
| 2025-05-29 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=81db8eca-8752-4d33-892a-4ee4b1a8d71d.pdf) |
| 2024-11-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34c1470b-5440-4155-952c-d3469c563b12.pdf) |
| 2024-08-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa5ac5be-3b4e-409c-b570-b70ec1d10097.pdf) |
| 2024-05-29 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=80a7c2af-df0b-4df3-b555-068581f0d013.pdf) |
| 2024-02-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=37f00549-74e9-4fd7-be45-4330f75ced2e.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2024 | [Concall - Sep 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b55029a5-57d1-46ab-b826-fb2cc20bb124.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ecd03561-909d-4fcd-b57b-fb455bd2da51.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5977d57d-33d7-4430-a03c-1d73c30b518f.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/084f43ef-0358-4329-8a21-a5ff89874101.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/42c6bd93-e92a-4faf-a759-d5d6eaad0470.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/df327d08-d0a1-4e17-ae08-bf3b4fe629f4.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/29448a73-7ab6-445b-9a4e-21fd9d2ce5ef.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/005174ce-2452-41d5-ab5e-1d0f3f147c52.pdf) |
| Mar 2025 | [Concall - Mar 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/111cd47b-bf95-48b5-87c1-5a8fbed12ef4.pdf) |
| Jun 2026 | [Concall - Jun 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/65750fe0-662a-48ca-a015-e770c0a7f0e7.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8 May - US FDA inspected Taloja CRO facility on 8 May 2026; no Form 483 issued. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 8 May - US FDA inspected Taloja CRO facility on 8 May 2026; no Form 483 issued.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f4001287-c928-4589-80d7-1dbc492327e1.pdf) |
| 7 Apr - Alkem launched A to Z Daily multivitamin supplement on 7 April 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 7 Apr - Alkem launched A to Z Daily multivitamin supplement on 7 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/43641e72-d1ab-455f-bbf6-15f6b8a08061.pdf) |
| 6 Mar - On 06-Mar-2026 Alkem Medtech executed SPA to acquire 51–55% stake in Occlutech Holding AG. | [Announcement under Regulation 30 (LODR)-Updates on Acquisition 6 Mar - On 06-Mar-2026 Alkem Medtech executed SPA to acquire 51–55% stake in Occlutech Holding AG.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ae31b2de-809d-47ee-a10b-b4bcadafb317.pdf) |
| 5 May - Commissioner (Appeals) dropped Rs 69.65 crore GST demand, interest and penalty; order received 4 May 2026. | [Regulation 30 Of SEBI (LODR) Regulations, 2015. 5 May - Commissioner (Appeals) dropped Rs 69.65 crore GST demand, interest and penalty; order received 4 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/582b80d9-ad7a-4792-84bb-4763a4ebdd19.pdf) |
| 4 Feb - Newspaper Publication of Unaudited Results for the Quarter and nine months ended 31st december 2025 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Feb - Newspaper Publication of Unaudited Results for the Quarter and nine months ended 31st december 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e3718c34-9f7d-4d93-a3be-b83da58f9001.pdf) |
| 31 Mar - Ravinder Chaklam superannuated effective 24 Mar 2026; Mukesh Tiwari moved to subsidiary effective 1 Oct 2025. | [Announcement under Regulation 30 (LODR)-Change in Management 31 Mar - Ravinder Chaklam superannuated effective 24 Mar 2026; Mukesh Tiwari moved to subsidiary effective 1 Oct 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3352d383-c243-469f-89bb-a43470dcf8e1.pdf) |
| 30 Mar - Incorporated Alkem Pharmaceuticals Scientific Office FZ LLC (WOS) in Dubai; subscribed capital AED 3,670,000; incorporated 4 Feb 2026. | [Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Incorporation Of Wholly Owned Subsidiary Of The Company As A ''Scientific Office''. 30 Mar - Incorporated Alkem Pharmaceuticals Scientific Office FZ LLC (WOS) in Dubai; subscribed capital AED 3,670,000; incorporated 4 Feb 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0fe1f74a-6601-465d-a243-733526fe28c6.pdf) |
| 28 Feb - Sterling Tools: Ms. Kamal Malik resigned as Company Secretary & Compliance Officer effective COB 28 Feb 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 28 Feb - Sterling Tools: Ms. Kamal Malik resigned as Company Secretary & Compliance Officer effective COB 28 Feb 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/76a9ef35-52de-440e-b3ac-b8896fc5c070.pdf) |
| 27 Mar - Alkem appointed Mr. Samsher Kumar Deo as senior management, effective 27 March 2026; 29 years' sales experience. | [Announcement under Regulation 30 (LODR)-Change in Management 27 Mar - Alkem appointed Mr. Samsher Kumar Deo as senior management, effective 27 March 2026; 29 years' sales experience.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ecbbfd5c-21b8-490f-b300-0fa1bcdd2b1c.pdf) |
| 25 Feb - Newspaper publication w.r.t. Postal Ballot Notice and Intimation of Remote e-voting facility. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Feb - Newspaper publication w.r.t. Postal Ballot Notice and Intimation of Remote e-voting facility.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/02cdf68d-9d6a-4af2-9c9d-c21a45795177.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/17dc6456-8643-49d4-a860-eb0cd3796e43.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/08670de9-d763-4d1b-9412-f1524ad094d0.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e4b7ba2c-780e-43ab-a6a9-a56f2a6f4148.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/92259065-d6cd-48d1-9d2c-d5dd267da373.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:35:52.254Z.